188 related articles for article (PubMed ID: 22240798)
1. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer.
Ettl T; Baader K; Stiegler C; Müller M; Agaimy A; Zenk J; Kühnel T; Gosau M; Zeitler K; Schwarz S; Brockhoff G
Br J Cancer; 2012 Feb; 106(4):719-26. PubMed ID: 22240798
[TBL] [Abstract][Full Text] [Related]
2. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.
Ach T; Zeitler K; Schwarz-Furlan S; Baader K; Agaimy A; Rohrmeier C; Zenk J; Gosau M; Reichert TE; Brockhoff G; Ettl T
Virchows Arch; 2013 Jan; 462(1):65-72. PubMed ID: 23242174
[TBL] [Abstract][Full Text] [Related]
3. Predictors of cervical lymph node metastasis in salivary gland cancer.
Ettl T; Gosau M; Brockhoff G; Schwarz-Furlan S; Agaimy A; Reichert TE; Rohrmeier C; Zenk J; Iro H
Head Neck; 2014 Apr; 36(4):517-23. PubMed ID: 23780687
[TBL] [Abstract][Full Text] [Related]
4. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S
Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363
[TBL] [Abstract][Full Text] [Related]
5. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.
Suzuki S; Dobashi Y; Minato H; Tajiri R; Yoshizaki T; Ooi A
Virchows Arch; 2012 Sep; 461(3):271-82. PubMed ID: 22828828
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
Vidal L; Tsao MS; Pond GR; Cohen EE; Cohen RB; Chen EX; Agulnik M; Hotte S; Winquist E; Laurie S; Hayes DN; Ho J; Dancey J; Siu LL
Head Neck; 2009 Aug; 31(8):1006-12. PubMed ID: 19309723
[TBL] [Abstract][Full Text] [Related]
8. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
[TBL] [Abstract][Full Text] [Related]
9. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466
[TBL] [Abstract][Full Text] [Related]
11. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.
Freeman SS; Allen SW; Ganti R; Wu J; Ma J; Su X; Neale G; Dome JS; Daw NC; Khoury JD
Cancer; 2008 Sep; 113(6):1453-61. PubMed ID: 18704985
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
[TBL] [Abstract][Full Text] [Related]
13. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
[TBL] [Abstract][Full Text] [Related]
14. Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands.
Lujan B; Hakim S; Moyano S; Nadal A; Caballero M; Diaz A; Valera A; Carrera M; Cardesa A; Alos L
Br J Cancer; 2010 Aug; 103(4):510-6. PubMed ID: 20664595
[TBL] [Abstract][Full Text] [Related]
15. Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.
Stankiewicz E; Prowse DM; Ng M; Cuzick J; Mesher D; Hiscock F; Lu YJ; Watkin N; Corbishley C; Lam W; Berney DM
PLoS One; 2011 Mar; 6(3):e17517. PubMed ID: 21407808
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations and PTEN loss in salivary duct carcinomas.
Griffith CC; Seethala RR; Luvison A; Miller M; Chiosea SI
Am J Surg Pathol; 2013 Aug; 37(8):1201-7. PubMed ID: 23851329
[TBL] [Abstract][Full Text] [Related]
17. The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer.
Pattje WJ; Schuuring E; Mastik MF; Slagter-Menkema L; Schrijvers ML; Alessi S; van der Laan BF; Roodenburg JL; Langendijk JA; van der Wal JE
Br J Cancer; 2010 Jun; 102(12):1778-85. PubMed ID: 20502457
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
19. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
de Graeff P; Crijns AP; Ten Hoor KA; Klip HG; Hollema H; Oien K; Bartlett JM; Wisman GB; de Bock GH; de Vries EG; de Jong S; van der Zee AG
Br J Cancer; 2008 Jul; 99(2):341-9. PubMed ID: 18628764
[TBL] [Abstract][Full Text] [Related]
20. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.
Cros J; Sbidian E; Hans S; Roussel H; Scotte F; Tartour E; Brasnu D; Laurent-Puig P; Bruneval P; Blons H; Badoual C
Ann Oncol; 2013 Oct; 24(10):2624-2629. PubMed ID: 23933559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
